San Diego, California--(Newsfile Corp. - July 26, 2021) - The Frequency Therapeutics, Inc. (NASDAQ: FREQ) class action lawsuit charges Frequency Therapeutics and its CEO with violations of the Securities Exchange Act of 1934 and seeks to represent purchasers of Frequency Therapeutics common stock between November 16, 2020 and March 22, 2021, inclusive (the "Class Period"). The Frequency Therapeutics class action lawsuit (Evans v. Frequency Therapeutics, Inc., No. 21-cv-10933) was commenced on June 3, 2021 in the District of Massachusetts and is assigned to Judge William G. Young. A similar lawsuit (Hingston v. Frequency Therapeutics, Inc., No. 21-cv-11040) is also pending in the District of Massachusetts.
If you suffered substantial losses and wish to serve as lead plaintiff of the Frequency Therapeutics class action lawsuit, please provide your information by clicking here. You can also contact attorney J.C. Sanchez of Robbins Geller by calling 800/449-4900 or via e-mail at email@example.com. Lead plaintiff motions for the Frequency Therapeutics class action lawsuit must be filed with the court no later than August 2, 2021.
CASE ALLEGATIONS: The Frequency Therapeutics class action lawsuit alleges that, shortly after launching the Phase FX-322 2a trial, Frequency Therapeutics and its Chief Executive Officer, defendant David L. Lucchino, learned that the Phase 2a trial results revealed no discernable difference between FX-322 and the placebo. The Frequency Therapeutics class action lawsuit further alleges that, while Frequency Therapeutics' stock price remained artificially inflated, defendant Lucchino sold over 350,000 Frequency Therapeutics shares, pocketing over $10.5 million.
On March 23, 2021, Frequency Therapeutics disclosed deeply disappointing interim Phase 2a results, revealing that subjects with mild to moderate severe sensorineural hearing loss did not demonstrate improvements in hearing measures versus placebo. On this news, Frequency Therapeutics' stock price fell by nearly 78%, damaging investors.
THE LEAD PLAINTIFF PROCESS: The Private Securities Litigation Reform Act of 1995 permits any investor who purchased Frequency Therapeutics common stock during the Class Period to seek appointment as lead plaintiff in the Frequency Therapeutics class action lawsuit. A lead plaintiff is generally the movant with the greatest financial interest in the relief sought by the putative class who is also typical and adequate of the putative class. A lead plaintiff acts on behalf of all other class members in directing the Frequency Therapeutics class action lawsuit. The lead plaintiff can select a law firm of its choice to litigate the Frequency Therapeutics class action lawsuit. An investor's ability to share in any potential future recovery of the Frequency Therapeutics class action lawsuit is not dependent upon serving as lead plaintiff.
ABOUT ROBBINS GELLER RUDMAN & DOWD LLP: With 200 lawyers in 9 offices nationwide, Robbins Geller Rudman & Dowd LLP is the largest U.S. law firm representing investors in securities class actions. Robbins Geller attorneys have obtained many of the largest shareholder recoveries in history, including the largest securities class action recovery ever - $7.2 billion - in In re Enron Corp. Sec. Litig. The 2020 ISS Securities Class Action Services Top 50 Report ranked Robbins Geller first for recovering $1.6 billion for investors last year, more than double the amount recovered by any other securities plaintiffs' firm. Please visit https://www.rgrdlaw.com/firm.html for more information.
Past results do not guarantee future outcomes.
Services may be performed by attorneys in any of our offices.
Robbins Geller Rudman & Dowd LLP
655 W. Broadway, San Diego, CA 92101
J.C. Sanchez, 800-449-4900
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/91126